Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

PhoreMost Ltd.

PhoreMost has developed a next-generation phenotypic drug discovery technology called SITESEEKER®, which uses the power of live-cells to discern the best new targets for future therapy and crucially, how to drug them. Based on ‘Protein Interference’ (PROTEINi®); a new genome-wide target identification & validation platform created by PhoreMost, SITESEEKER® can now systematically reveal critical druggable target-sites in any particular disease setting and then convert this information rapidly into novel small-molecule therapeutics. Using SITESEEKER®, PhoreMost is exclusively developing first-in-class targets for a range of unmet diseases and will collaborate with other pharmaceutical companies also wishing to engage in ‘Drugging the Undruggable®’. *


Period Start 2015-04-07 established
Products Industry drug discovery
  Industry 2 Siteseeker® drug target discovery technology
Persons Person Torrance, Chris (PhoreMost 201504– CEO + Co-founder before Horizon Discovery Co-founder + Vernalis)
  Person 2 Milner, Jonathan (Abcam 201409 Deputy Chairman + largest shareholder before CEO + Co-founder)
Region Region Babraham, Cambridgeshire
  Country United Kingdom (GB)
  Street Building B580, Room 2011
Babraham Research Campus
  City CB22 3AT Babraham, Cambridgeshire
  Tel +44-1223-804163
    Address record changed: 2021-04-27
Basic data Employees n. a.
    * Document for �About Section�: 
Record changed: 2021-03-27


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for PhoreMost Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top